For percentage of patients achieving specified reduction in disease activity, iberdomide superior to placebo only at highest dose tested<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 16, 2022 (HealthDay News) — For patients with systemic lupus erythematosus (SLE), iberdomide at a higher dose is superior to placebo for the rate of response indicating reduction in disease activity, according to a study published in the March 17 issue of the New England Journal of Medicine<\/em>.<\/p>\n Joan T. Merrill, M.D., from the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues randomly assigned 288 patients with SLE to receive oral iberdomide (at a dose of 0.45, 0.30, or 0.15 mg) or placebo once daily for 24 weeks, in addition to standard medications in a 2:2:1:2 ratio (81, 82, 42, and 83 patients, respectively). The primary end point was a response on the SLE Responder Index (SRI-4) at week 24.<\/p>\n The researchers found that the percentage of patients with an SRI-4 response was 54, 40, 48, and 35 percent in the iberdomide 0.45-, 0.30-, and 0.15-mg, and placebo groups, respectively, at week 24 (adjusted difference between iberdomide 0.45 mg versus placebo: 19.4 percentage points). There were no significant differences observed between the iberdomide 0.30- and 0.15-mg groups and the placebo group. Adverse events associated with iberdomide included urinary tract and upper respiratory tract infections and neutropenia.<\/p>\n “In patients with SLE, iberdomide at the highest dose, but not at lower doses, was superior to placebo with respect to the primary end point of an SRI-4 response at 24 weeks,” the authors write. “Longer and larger trials are warranted to determine the effect and safety of iberdomide in patients with SLE.”<\/p>\n The study was funded by Bristol Myers Squibb; Celgene, a subsidiary of Bristol Myers Squibb, manufactures iberdomide.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n